GSK2398852, now known as Dezamizumab, is a groundbreaking monoclonal antibody currently under therapeutic assessment for its capacity to inhibit the enzyme CD22, a vital factor of B-cell operation. This treatment approach presents significant hope for alleviating immune-mediated disorders, particularly those involving dysregulated B-cell behavior.